Novartis (NVS) Stock Forecast & Price Target

$97.51 +0.40 (+0.41%)

(As of 11:58 AM ET)

Novartis - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 9 Analyst Ratings

Sell
2

Hold
7

Buy
0

Based on 9 Wall Street analysts who have issued ratings for Novartis in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 9 analysts, 2 have given a sell rating, and 7 have given a hold rating for NVS.

Consensus Price Target

$121.50
24.60% Upside

According to the 9 analysts' twelve-month price targets for Novartis, the average price target is $121.50. The highest price target for NVS is $130.00, while the lowest price target for NVS is $114.00. The average price target represents a forecasted upside of 24.60% from the current price of $97.51.

Get the Latest News and Ratings for NVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novartis and its competitors.

NVS Analyst Ratings Over Time

Type	Current Forecast 12/24/23 to 12/23/24	1 Month Ago 11/24/23 to 11/23/24	3 Months Ago 9/25/23 to 9/24/24	1 Year Ago 12/24/22 to 12/24/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	1 Buy rating(s)
Hold	7 Hold rating(s)	8 Hold rating(s)	7 Hold rating(s)	4 Hold rating(s)
Sell	2 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$121.50	$121.50	$120.70	$85.00
Forecasted Upside	24.60% Upside	16.51% Upside	3.67% Upside	-13.92% Downside
Consensus Rating	Reduce	Reduce	Reduce	Hold

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

NVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novartis Stock vs. The Competition

Type	Novartis	Medical Companies	S&P 500
Consensus Rating Score	1.78	2.81	2.51
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	25.12% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Neutral News See Recent NVS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/4/2024	HSBC 3 of 5 stars		Downgrade	Hold ➝ Reduce
11/19/2024	Erste Group Bank 3 of 5 stars		Reiterated Rating	Buy ➝ Hold
10/30/2024	BMO Capital Markets 4 of 5 stars		Boost Target	Market Perform ➝ Market Perform	$118.00 ➝ $120.00	+8.53%
9/11/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$135.00 ➝ $130.00	+11.08%
9/5/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Quigley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$119.00 ➝ $121.00	+1.37%
9/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/19/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
6/24/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Field Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
1/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight	$114.00	+5.09%
4/19/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$75.00 ➝ $85.00	-13.28%
1/26/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
1/3/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:06 PM ET.

Should I Buy Novartis Stock? NVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, December 18, 2024. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

Novartis
Bull Case

Here are some ways that investors could benefit from investing in Novartis AG:

Novartis AG's stock is currently trading at $105.77, showing a recent increase of 0.9%. This positive price movement can indicate investor confidence and potential for further growth.
The company has a strong market capitalization of $216.19 billion, which reflects its stability and ability to withstand market fluctuations.
Recent analyst ratings show a consensus "Hold" rating with a price target averaging $121.50, suggesting that analysts believe the stock has room for growth without significant risk.
Institutional investors own 13.12% of Novartis AG's stock, indicating a level of trust and investment from large financial entities, which can be a positive signal for individual investors.
Novartis AG has a relatively low debt-to-equity ratio of 0.55, suggesting that the company is not overly reliant on debt for financing, which can reduce financial risk.

Novartis
Bear Case

Investors should be bearish about investing in Novartis AG for these reasons:

Several analysts have downgraded their ratings on Novartis AG, with Bank of America reducing its rating from "buy" to "neutral," which may indicate concerns about the company's future performance.
The stock has experienced fluctuations, with a 12-month low of $92.35, suggesting potential volatility that could deter risk-averse investors.
There is a notable presence of sell ratings among analysts, with two analysts rating the stock as a sell, which could reflect underlying issues that may affect the company's growth prospects.
Despite recent positive movements, the stock's price-to-earnings ratio of 12.28 may suggest that it is not undervalued compared to its earnings, which could limit upside potential.
Recent changes in institutional holdings, such as Timber Creek Capital Management LLC reducing its stake by 16.9%, may signal a lack of confidence among some investors regarding the company's future performance.

NVS Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Novartis is $121.50, with a high forecast of $130.00 and a low forecast of $114.00.
: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last twelve months. There are currently 2 sell ratings and 7 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" NVS shares.
: According to analysts, Novartis's stock has a predicted upside of 24.60% based on their 12-month stock forecasts.
: Over the previous 90 days, Novartis's stock had 1 downgrade by analysts.
: Novartis has been rated by research analysts at BMO Capital Markets, Erste Group Bank, and HSBC in the past 90 days.
: Analysts like Novartis less than other "medical" companies. The consensus rating for Novartis is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Has Trump Finally Gone Too Far? (Ad)

This page (NYSE:NVS) was last updated on 12/23/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novartis (NVS) Stock Forecast & Price Target